Modulo Bio

Modulo Bio is developing a platform that couples machine learning and cell-based models to reprogram the neuroimmune system and slow or reverse neurological diseases. The platform engineers brain immune cells, called microglia, from human tissues at scale and, using neuroimmune system models, assesses how the microglia behave under different conditions. The platform can be used to discover and repurpose therapeutic targets, as well as identify new therapies. Modulo Bio’s lead program is a development candidate stage small molecule targeting a genetic subpopulation of ALS defined by the C9ORF72 mutation.